Clinical Trials

Leukemia, Myeloid, Acute

NCT03514017 2026-03-02

Ibrutinib and PD-1 Blockade in High Risk Lymphocytic Leukemia

Phase 2 Terminated

5 enrolled 11 charts

Phase 2 Active not recruiting

Bone Marrow Diseases, Hematologic Diseases, Leukemia, Leukemia, Lymphocytic, Chronic, B-Cell

NCT03516279 2026-03-02

Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease

40 enrolled

Leukemia, Myeloid, Chronic-Phase, Neoplasm, Residual

NCT05005442 2026-02-19

A Study of Pembrolizumab/Vibostolimab (MK-7684A) in Relapsed/Refractory Hematological Malignancies (MK-7684A-004, KEYVIBE-004)

192 enrolled 22 charts

Hematologic Neoplasms

NCT03204188 2026-01-30

Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

15 enrolled 9 charts

Chromosome 17 deletion, Leukemia, Lymphocytic, Chronic, B-Cell

NCT06863402 2025-12-23

Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype

Phase 2 Recruiting

32 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT02768792 2024-09-25

High Dose Cytarabine Followed by Pembrolizumab in Relapsed/Refractory AML

38 enrolled 14 charts

Leukemia, Myeloid, Acute

NCT02332980 2024-01-03

Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas

65 enrolled 21 charts

Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone

NCT02771197 2023-09-28

Lymphodepletion and Anti-PD-1 Blockade to Reduce Relapse in AML Patient Not Eligible for Transplant

20 enrolled 9 charts

Leukemia, Myeloid, Acute

NCT02845297 2023-03-09

Study of Azacitidine in Combination With Pembrolizumab in R/R AML Patients and in Newly Diagnosed Older Patients

67 enrolled 10 charts

Leukemia, Myeloid, Acute

NCT02708641 2021-08-10

A Phase II Study of Pembrolizumab as Post-Remission Treatment of Patients ≥ 60 With AML

12 enrolled 13 charts

Leukemia, Myeloid, Acute

NCT04016116 2020-05-27

Dual PD-1 and JAK2 Inhibition in Hematological Malignancies

Phase 2 Withdrawn